EZZ Life Science Holdings Limited
EZZ Life Science Holdings Limited (EZZ.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for EZZ Life Science Holdings Limited (EZZ.AX), covering cash flow, earnings, and balance sheets.
EZZ Life Science Holdings Limited (EZZ.AX) Income Statement & Financial Overview
Access detailed annual and quarterly income data for EZZ Life Science Holdings Limited EZZ.AX financial performance.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $44.75M | $21.70M | $22.02M | $11.02M |
| Cost of Revenue | $10.01M | $7.14M | $5.34M | $2.32M |
| Gross Profit | $34.73M | $14.56M | $16.68M | $8.70M |
| Gross Profit Ratio | $0.78 | $0.67 | $0.76 | $0.79 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $26.51M | $13.06M | $13.82M | $6.73M |
| Operating Expenses | $26.51M | $13.06M | $13.82M | $7.14M |
| Total Costs & Expenses | $36.52M | $20.20M | $19.16M | $9.46M |
| Interest Income | $148808.00 | $46930.00 | $18398.00 | $5244.00 |
| Interest Expense | $10528.00 | $14226.00 | $7911.00 | $0.00 |
| Depreciation & Amortization | $200233.00 | $191304.00 | $123843.00 | $6230.00 |
| EBITDA | $8.64M | $1.73M | $3.25M | $1.45M |
| EBITDA Ratio | $0.19 | $0.08 | $0.14 | $0.13 |
| Operating Income | $8.22M | $1.49M | $2.86M | $1.45M |
| Operating Income Ratio | $0.18 | $0.07 | $0.13 | $0.13 |
| Other Income/Expenses (Net) | $209911.00 | $32704.00 | $260640.00 | $112820.00 |
| Income Before Tax | $8.43M | $1.53M | $3.12M | $1.56M |
| Income Before Tax Ratio | $0.19 | $0.07 | $0.14 | $0.14 |
| Income Tax Expense | $2.61M | $383724.00 | $791642.00 | $395821.00 |
| Net Income | $5.82M | $1.14M | $2.33M | $1.17M |
| Net Income Ratio | $0.13 | $0.05 | $0.11 | $0.11 |
| EPS | $0.13 | $0.03 | $0.05 | $0.03 |
| Diluted EPS | $0.13 | $0.03 | $0.05 | $0.03 |
| Weighted Avg Shares Outstanding | $43.46M | $42.70M | $42.70M | $42.66M |
| Weighted Avg Shares Outstanding (Diluted) | $43.46M | $42.70M | $42.70M | $42.65M |
The company's financials show resilient growth, with revenue advancing from $11.02M in Q3 2023 to $44.75M in Q4 2024. Gross profit remained healthy with margins at 78% in Q4 2024 compared to 79% in Q3 2023. Operating income hit $8.22M last quarter, sustaining a consistent 18% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $8.64M. Net income rose to $5.82M, while earnings per share reached $0.13. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan